文献速递白血病

基于DNA甲基化模式检测急性髓系白血病可测量残留病

Investigation of measurable residual disease in acute myeloid leukemia by DNA methylation patterns.
PubMed 文献 · Leukemia · 2021-06-15

本研究提出基于AML相关DNA甲基化模式的替代方法评估可测量残留病(MRD)。鉴定出4个CpG位点组合可区分健康与AML样本,并训练浅层与深度学习算法识别异常甲基化模式。在随访样本中,即使判为MRD阴性的样本异常比率也常高于健康对照,可能反映克隆性造血;但健康样本亦含少量异常判读,故尚不能可靠区分MRD阳性与阴性。

要点

  • 4个CpG位点组合可可靠区分健康与AML样本。
  • 亚硫酸氢盐扩增子测序显示异常甲基化模式在两条等位基因上对称。
  • 该方法尚不能可靠区分MRD阳性与阴性样本。

核心结论

  • 靶向DNA甲基化分析可可靠区分恶性与健康样本。
  • 该方法尚不能可靠区分MRD阳性与阴性样本。

研究设计与样本

  • 研究鉴定AML相关异常DNA甲基化模式并训练浅层与深度学习算法识别异常模式。
  • 方法在含与不含MRD的随访样本中测试。

主要发现

  • 鉴定出4个CpG位点组合可可靠区分健康与AML样本。
  • 亚硫酸氢盐扩增子测序显示异常DNA甲基化模式在两条等位基因上对称。
  • 判为MRD阴性的样本异常比率常高于健康对照,可能反映克隆性造血。
  • 健康样本亦含少量异常判读的DNA甲基化 reads。

临床怎么用

  • 靶向DNA甲基化分析可作为区分恶性与健康样本的辅助手段。
  • 目前尚不宜单独用于MRD阳性与阴性的临床判定。

局限性

  • 健康样本亦含少量异常判读的DNA甲基化 reads,影响MRD阴性/阳性区分可靠性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Assessment of measurable residual disease (MRD) upon treatment of acute myeloid leukemia (AML) remains challenging. It is usually addressed by highly sensitive PCR- or sequencing-based screening of specific mutations, or by multiparametric flow cytometry. However, not all patients have suitable mutations and heterogeneity of surface markers hampers standardization in clinical routine. In this study, we propose an alternative approach to estimate MRD based on AML-associated DNA methylation (DNAm) patterns. We identified four CG dinucleotides (CpGs) that commonly reveal aberrant DNAm in AML and their combination could reliably discern healthy and AML samples. Interestingly, bisulfite amplicon sequencing demonstrated that aberrant DNAm patterns were symmetric on both alleles, indicating that there is epigenetic crosstalk between homologous chromosomes. We trained shallow-learning and deep-learning algorithms to identify anomalous DNAm patterns. The method was then tested on follow-up samples with and without MRD. Notably, even samples that were classified as MRD negative often revealed higher anomaly ratios than healthy controls, which may reflect clonal hematopoiesis. Our results demonstrate that targeted DNAm analysis facilitates reliable discrimination of malignant and healthy samples. However, since healthy samples also comprise few abnormal-classified DNAm reads the approach does not yet reliably discriminate MRD positive and negative samples.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Božić T, Kuo CC, Hapala J, et al. Investigation of measurable residual disease in acute myeloid leukemia by DNA methylation patterns. Leukemia. 2021. PMID: 34131280. doi:10.1038/s41375-021-01316-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。